Rathbones Group PLC Cuts Position in STERIS plc $STE

Rathbones Group PLC cut its holdings in STERIS plc (NYSE:STE) by 2.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 108,600 shares of the medical equipment provider’s stock after selling 3,281 shares during the period. Rathbones Group PLC owned about 0.11% of STERIS worth $26,872,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Jones Financial Companies Lllp boosted its position in STERIS by 46.1% in the first quarter. Jones Financial Companies Lllp now owns 1,106 shares of the medical equipment provider’s stock worth $251,000 after purchasing an additional 349 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of STERIS by 32.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 242,732 shares of the medical equipment provider’s stock valued at $55,015,000 after purchasing an additional 59,264 shares during the last quarter. Empowered Funds LLC raised its stake in shares of STERIS by 16.1% during the 1st quarter. Empowered Funds LLC now owns 2,303 shares of the medical equipment provider’s stock worth $522,000 after purchasing an additional 319 shares during the period. Woodline Partners LP raised its stake in shares of STERIS by 40.0% during the 1st quarter. Woodline Partners LP now owns 8,300 shares of the medical equipment provider’s stock worth $1,881,000 after purchasing an additional 2,372 shares during the period. Finally, Jane Street Group LLC boosted its holdings in shares of STERIS by 38.9% in the 1st quarter. Jane Street Group LLC now owns 20,716 shares of the medical equipment provider’s stock worth $4,695,000 after buying an additional 5,803 shares during the last quarter. 94.69% of the stock is owned by hedge funds and other institutional investors.

STERIS Price Performance

Shares of NYSE:STE opened at $230.49 on Monday. The company has a quick ratio of 1.75, a current ratio of 2.48 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $22.60 billion, a PE ratio of 32.15 and a beta of 1.05. STERIS plc has a twelve month low of $204.90 and a twelve month high of $269.44. The company has a 50-day moving average price of $254.37 and a two-hundred day moving average price of $251.55.

STERIS (NYSE:STE) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. The company’s revenue was up 9.2% on a year-over-year basis. During the same period last year, the company earned $2.32 EPS. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. Equities analysts forecast that STERIS plc will post 9.08 EPS for the current year.

STERIS Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Tuesday, February 17th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Tuesday, February 17th. This represents a $2.52 dividend on an annualized basis and a yield of 1.1%. STERIS’s payout ratio is presently 35.15%.

Insider Activity

In other STERIS news, Director Cynthia L. Feldmann sold 3,098 shares of the stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $237.21, for a total transaction of $734,876.58. Following the sale, the director owned 705 shares in the company, valued at $167,233.05. This represents a 81.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.07% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms recently issued reports on STE. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a report on Friday, January 9th. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $275.20.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.